Maryland is considered one of the more progressive states when it comes to testing and implementing innovative models of care and healthcare reform. The state has passed many payer and provider legislations, keeping the healthcare ecosystem dynamic. Maryland's exchange premiums dropped three years in a row and has seen positive changes following a disappointing start. Lack of growth in commercial enrollment remains a challenge for most managed care organizations in Maryland, although some carriers have seen growth of consumer-directed health plans and self-insured products. As the state continues to accept new residents under its expanded Medicaid program, HealthChoice, to 138 percent of the federal poverty level, competition between participating MCOs will increase as they seek to gain a bigger share of this growing segment. The largest health systems have entered the managed Medicare and Medicaid markets with product offerings.


Related Reports

Systemic Lupus Erythematosus - Landscape & Forecast - Disease Landscape & Forecast

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course,...

View Details

Systemic Lupus Erythematosus | Disease Landscape and Forecast | G7 | 2020

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be hig...

View Details

Systemic Lupus Erythematosus - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) 2021

MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serio...

View Details

Systemic Lupus Erythematosus - Access & Reimbursement - Detailed, Expanded Analysis (US)

The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta—which launched in 2011&...

View Details